pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Big Pharma · news · pharmadog
← back to Big Pharma
News · Big Pharma
309
stories
Oct 8, 26
Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run
fiercebiotech
Oct 7, 26
Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up
biospace
Oct 7, 26
TCGX launches $600M fund to bankroll Asian biotechs
fiercebiotech
Oct 7, 26
Matchpoint nets $150M series B to take covalent med into clinic
fiercebiotech
Oct 7, 26
5 biggest venture capital raises of Q3 2026
biospace
Oct 6, 26
Big Pharma-backed Nuvig halts development of lead fusion protein in rare autoimmune disease
fiercebiotech
Oct 6, 26
ArriVent’s phase 3 lung cancer trial flops, sinking stock
fiercebiotech
Oct 6, 26
AstraZeneca hopes to ‘achieve amazing things’ with new Kendall Square R&D center
fiercebiotech
Oct 6, 26
TRex Bio stomps toward $111M IPO, as Retension and Lycia also gear up to go public
fiercebiotech
Oct 5, 26
Lilly doubles down on Gate alliance to unlock new drug class with another $870M+ in biobucks
biospace
Oct 5, 26
Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset
biospace
Oct 5, 26
Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck
biospace
Oct 5, 26
Genentech pays Alector $100M for preclinical Parkinson’s prospect
fiercebiotech
Oct 5, 26
Trio of scientists who developed neuron light switches win Nobel Prize in Physiology or Medicine
fiercebiotech
Oct 5, 26
CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug
fiercebiotech
Oct 5, 26
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
fiercebiotech
Oct 5, 26
Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
biospace
Oct 2, 26
Gate CEO sees expanded $870M pact with Lilly as ‘vote of confidence’ in biotech’s platform
fiercebiotech
Oct 2, 26
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
Oct 2, 26
STAT+: Lilly bypasses Australian pharmacies with DTC model
stat
Oct 1, 26
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
Oct 1, 26
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
biospace
Oct 1, 26
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
fiercebiotech
Sep 30, 26
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
Sep 29, 26
Summit snags $2B investment from AstraZeneca, clearing financial overhang
biospace
Sep 29, 26
There Is No Such Thing as a Typical Biotech
fiercebiotech
Sep 29, 26
Biopharma recruiters see ‘signs of recovery’ as layoffs remain cool in Q3’26
fiercebiotech
Sep 29, 26
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
Sep 28, 26
STAT+: Merck discontinues a crucial antibiotic despite concerns over superbug resistance
stat
Sep 28, 26
ai3Bio emerging from stealth to ‘take the gun out of the hands of the immune system’
fiercebiotech
← prev
page 5 of 11
next →